Tarlochan S Niijar

Title: An Overview of Inventor Tarlochan S. Niijar

Introduction

Tarlochan S. Niijar is a distinguished inventor based in Orinda, California. With a significant contribution to the field of neuroscience and therapeutics, he holds one patent that showcases his innovative approach to addressing complex neurological conditions.

Latest Patents

Niijar’s notable patent focuses on "Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein." This invention presents an advanced methodology, involving the use of monoclonal antibody 5C1 and related antibodies associated with a monovalent binding entity designed for a blood-brain barrier receptor. The 5C1 antibody targets an epitope within residues 118-126 of alpha-synuclein. The applications of these antibodies are far-reaching, particularly for the treatment and diagnosis of synucleinopathies like Lewy body diseases, including Parkinson's disease, diffuse Lewy body disease, and Alzheimer's disease among others.

Career Highlights

Tarlochan Niijar has built an impressive career, having worked with prominent companies such as Prothena Bioscience Limited and Hoffmann-La Roche Inc. His expertise in the development of therapeutic solutions is recognized across the industry.

Collaborations

Throughout his career, Niijar has collaborated with notable professionals in the field, including Robin McDaid Barbour and Kate Dora Games-Thiel. These partnerships have enhanced his research and contributed to significant advancements in neuroscience.

Conclusion

Tarlochan S. Niijar stands as an influential figure within the realm of medical innovations, particularly related to neurological disorders. His pioneering patent reflects a commitment to improving patient outcomes through targeted therapies, and his collaborations underscore the collaborative spirit that drives advancements in science and technology.